A Study of IN026 in Participants With Refractory Gout

Inclusion Criteria: 1. Can voluntarily sign the informed consent form (ICF) and comply with ICF and study protocol requirements. 2. Male or female, 18-75 years old (inclusive) at screening. 3. Meet 2015 ACR/EULAR gout classification criteria, in the intercritical phase of gout or acute flare resolved ≥2 weeks at screening. 4. Serum uric acid ≥420 μmol/L (7 mg/dl) at screening. 5. Meet the definition of refractory gout (poor uric acid control accompanied by severe gout symptoms) Exclusion Criteria: 1. Gout secondary to radiotherapy/chemotherapy, lead poisoning, organ transplantation, tumor, etc. at screening/baseline. 2. Rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at screening/baseline. 3. Glucose-6-phosphate dehydrogenase (G6PD) deficiency history, or G6PD level below normal lower limit. 4. Positive HBsAg; HCV antibody positive is excluded except those with sustained HCV-RNA negativity after standard treatment; HIV antibody positive; active syphilis. 5. Presence of chronic liver diseases including active hepatitis, cirrhosis and alcoholic liver disease. 6. Participants with a history of any of the following: serious cardiovascular diseases within 6 months prior to screening; or serious diseases of the digestive, respiratory, urinary, musculoskeletal, neuropsychiatric, hematological, or immune systems within 3 months prior to screening. 7. Prolonged QTcF at screening. 8. Uncontrolled or untreated hypertension at screening. 9. Participants who have received medications that may affect endpoint assessment, such as other urate-lowering therapies, mRNA-LNP vaccine, PEGylated drugs and uricase agents. 10. History of severe allergy, or known allergy to IN026 or its components. 11. Participation in other clinical trials within 30 days prior to screening. 12. Participants with poor compliance, or those deemed otherwise unsuitable for this study by the investigator.